entertainment -WSS

entertainment

author：leisure time 2025-09-29 16:45:20 - browse：7669

Intellia Therapeutics said Sunday that the first 10 patients to receive a CRISPR-based treatment for hereditary angioedema, a genetic disease, saw their swelling attacks — the condition’s hallmark symptom — virtually eliminated for an average of 20 months and counting.

The attacks were reduced by an average of 98%. One patient has remained attack-free for 26 months. Two patients who suffered particularly frequent attacks, experiencing 14 and 16.8 per month, respectively, have now gone more than 20 months since their last attack.

No patient has had an attack in the last 11 months of follow-up, according to the data presented at the European Academy of Allergy and Clinical Immunology Congress. All side effects were either grade 1 or 2 on a 5-grade scale.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Slovenia has suffered its worst

WSS

Why are Kaiser Permanente staff considering a strike?

Doctors are clamoring for more clarity on Paxlovid prescribing

Why are Kaiser Permanente staff considering a strike?

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Readout LOUD podcast: possible new ALS drug, artificial wombs

How CRISPR works, explained in two minutes

entertainment

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Dobbs anniversary: the lost opportunity of abortion as health care

Drug for rare kidney disease narrowly misses mark in clinical trial

The cancer drug shortage isn’t new — and neither are the solutions

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

After affirmative action ruling, medical educators look to 'holistic review'

Failure, not just success, should guide future doctors

Activists slam private health insurers over coverage restrictions

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Trump demands the U.S. pay no more for drugs than other countries … again

With heat waves through August, officials warn of health risks

hotspot

Election results set back Medicaid expansion plans

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Senators: Long

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Election results set back Medicaid expansion plans

Second xenotransplant done with gene

hotspot

Wikipedia

knowledge

focus